Here's how PUBMED.NCBI.NLM.NIH.GOV makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

PUBMED . NCBI . NLM . NIH . GOV {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Pubmed.ncbi.nlm.nih.gov Make Money
  6. Keywords
  7. Topics
  8. Social Networks
  9. External Links
  10. Analytics And Tracking
  11. Libraries
  12. CDN Services

We are analyzing https://pubmed.ncbi.nlm.nih.gov/31984306/.

Title:
Effects of Rivaroxaban on Biomarkers of Coagulation and Inflammation: A Post Hoc Analysis of the X-VeRT Trial - PubMed
Description:
<span><b>Introduction</b> This X-VeRT (eXplore the efficacy and safety of once-daily oral riVaroxaban for the prevention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion) substudy evaluated the effects of treatment with rivaroxaban or a vitamin-K antago</span> …
Website Age:
27 years and 8 months (reg. 1997-10-02).

Matching Content Categories {πŸ“š}

  • Health & Fitness
  • Non-Profit & Charity
  • Science

Content Management System {πŸ“}

What CMS is pubmed.ncbi.nlm.nih.gov built with?

Custom-built

No common CMS systems were detected on Pubmed.ncbi.nlm.nih.gov, and no known web development framework was identified.

Traffic Estimate {πŸ“ˆ}

What is the average monthly size of pubmed.ncbi.nlm.nih.gov audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Pubmed.ncbi.nlm.nih.gov Make Money? {πŸ’Έ}

We find it hard to spot revenue streams.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Pubmed.ncbi.nlm.nih.gov could have a money-making trick up its sleeve, but it's undetectable for now.

Keywords {πŸ”}

atrial, fibrillation, rivaroxaban, doi, pmid, cardioversion, oral, patients, pubmed, bayer, trial, pmc, levels, clinical, jan, biomarkers, nonvalvular, treatment, received, baseline, medical, boehringer, ingelheim, medtronic, epub, inflammation, xvert, cardiovascular, heart, anticoagulants, research, sanofiaventis, fees, study, fig, free, article, review, kim, conflict, interest, similar, articles, effects, kirchhof, vka, ddimer, hsil, biomarker, influence,

Topics {βœ’οΈ}

main page content high-sensitivity interleukin-6 [hs-il-6] nattokinase-bridging basic research protease-activated receptor signaling x-vert steering committee bristol-myers squibb/pfizer similar articles cited received research support medical research council resources bristol-myers squibb nonvalvular atrial fibrillation articles references bjΓΆrck direct oral anticoagulants high cardiovascular risk valvular atrial fibrillation acute atrial fibrillation atrial fibrillation developed x-vert trial cardiovascular research united states government intellectual property rights le heuzey jy comparative cardioprotective effectiveness low-dose aspirin warfarin therapy revisited atrial fibrillation cardioversion oral anticoagulant therapy post hoc analysis clin pharm ther large contemporary cohort global medical affairs congestive heart failure baseline biomarker levels global clinical development received personal fees device companies active rivaroxaban plasma concentration population-based study prospective national study british heart foundation prothrombin fragment [f1 received adequate anticoagulation received consultancy fees dose-adjusted vitamin results baseline levels pubmed kirchhof cardiovascular disease management pubmed haim pubmed hansen

External Links {πŸ”—}(38)

Analytics and Tracking {πŸ“Š}

  • Google Analytics
  • Google Analytics 4
  • Google Tag Manager

Libraries {πŸ“š}

  • Clipboard.js
  • jQuery
  • PhotoSwipe

CDN Services {πŸ“¦}

  • Ncbi

3.45s.